9%). Among then, E. coli accounted for 54 episodes (12.7% of total). 18 episodes were caused by ESBL producing enterobacteriaceae and all of them were ESBL E. coli (4.2% of the total episodes and 33.3% of all E. coli). 6 Episodes check details were treated with IP Imipenen/cilastatin with a dose ranged from 100–200 mg/L continuously. 2 of them required T/C removal and no death reported. IP meropenem was attempted in 5 episodes with a continuous dose of 200 mg/L in 2 and intermittent dose of 200–400 mg daily in the remaining. 1 episode has relapse (200 mg daily dose) and no death reported. Overall, no severe adverse reaction was noted, especially neurological complications. Chi-square

test for T/C removal rate showed P value 0.15. Conclusion: It appeared the number was inadequate to provide a meaningful statistical analysis.

Although the total dose of IP Tienam/Meropenem (up to 1.6 gram/day) were quite high, there was no specific neurological complications reported. However, lower dose was attempted successfully (Meropenem 400 mg/day), thus it may be a safer alternative while retaining the efficacy. Detailed pharmacokinetic study of Meropenem and large scale outcome study with various dosages are needed. YABUUCHI BMS-777607 datasheet JUNKO, MAKIISHI TETSUYA, MAEDA SAYAKO Division of Nephrology, Department of Internal Medicine, Otsu Red Cross Hospital Introduction: Twenty-four hour quantification of urinary protein collection (24-h proteinuria) has been the foundation for monitoring SB-3CT patients with various kidney diseases including membranous nephropathy (MN). However, because of the accumulation studies showing good correlations between random single-void (spot) urine protein to creatinine (P/C) ratio and 24-h proteinuria, spot urine P/C ratio is widely used instead of 24-h urine collection.

In the management of patients with MN, the amount of urine excretion is a marker for early diagnosis of relapse. However, the accuracy of spot urine P/C ratio has not been validated in MN. We aimed to evaluate its accuracy in patients with MN. Methods: Among 19 patients with MN who were treated at our institution between 2008 and 2013, 5 patients with at least one paired result of 24-h urine P/C ratio and a random spot urine P/C ratio were identified, and a total 51 paired results were examined. As a control, a total of 124 paired results from patients with primary (IgA nephropathy, n = 10, 52 pairs; minimal change nephrotic syndrome, n = 2, 18 pairs; focal segmental glomerulonephritis, n = 2, 37 pairs) and secondary (lupus nephritis, n = 1, 12 pairs) glomerulonephritis were also examined. All spot urine samples were obtained at daytime. The correlation and agreement between the P/C ratios in the two methods were assessed by Pearson correlation and the Bland-Altman procedure, respectively.